Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years

• Status: Unknown status
• Trial end date: 2021-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether the escalation dosage of Daunorubicin and cytarabine is effective and safety in the treatment of older adult Chinese acute myeloid leukemia（AML） patients aged 55 to 65 years.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jianxiang Wang
• Treatments: Cytarabine; Daunorubicin

Criteria

Inclusion Criteria:

• primary AML（except APL patients）;

• ECOG PS:0-2

Exclusion Criteria:

• AML patient who has already received induction treatment, no matter what the outcome is;

• Treatment-related AML;

• Active cancer patients who's condition need to be treated;

• The one with serious infectious diseases（eg.uncontrolled tuberculosis or invasive pulmonary aspergillosis）

• Active heart disease.